Clinical Trial Update: Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line Orelabrutinib plus Obinutuzumab (O2) for Marginal Zone Lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Huai'an First People's Hospital | Conditions: Marginal Zone Lymphoma | Phase 2 | Status: RECRUITING